Translation, cultural adaptation and validation of the Chinese Multimorbidity Treatment Burden Questionnaire(C-MTBQ): a study of older hospital patients.


Journal

Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626

Informations de publication

Date de publication:
22 Jun 2020
Historique:
received: 10 12 2019
accepted: 07 05 2020
entrez: 24 6 2020
pubmed: 24 6 2020
medline: 21 10 2020
Statut: epublish

Résumé

Due to an ageing population, multimorbidity is becoming more common. Treatment burden (the effort required of patients to look after their health and the impact this has on their wellbeing) is prevalent in patients with multimorbidity. The Multimorbidity Treatment Burden Questionnaire (MTBQ) is a patient-reported outcome measure of treatment burden that has been validated amongst patients with multimorbidity in the UK. The aim of this study was to translate and culturally adapt the MTBQ into Chinese and to assess its reliability and validity in elderly patients with multimorbidity in hospital. The original English version of the MTBQ was translated into Chinese using Brislin's model of cross-culture translation. The C-MTBQ was piloted on a sample of 30 elderly patients with multimorbidity prior to being completed by 156 Chinese elderly patients with multimorbidity recruited from a hospital in Zhengzhou, China. We examined the proportion of missing data, the distribution of responses and floor and ceiling effects for each question. Factor analysis, Cronbach's alpha, intraclass coefficient and Spearman's rank correlations assessed dimensional structure, internal consistency reliability, test-retest reliability and criterion validity, respectively. The average age of the respondents was 73.5 years (range 60-99 years). The median C-MTBQ global score was 20.8 (interquartile range 12.5-29.2). Significant floor effects were seen for all items. Factor analysis supported a three-factor structure. The C-MTBQ had high internal consistency (Cronbach's alpha coefficient, 0.76) and test-retest reliability (the intraclass correlation coefficient, 0.944), the correlations between every item and global scores scored > 0.4. The scale content validity index(S-CVI) was 0.89, and the item level content validity index(I-CVI)was 0.83 ~ 1.00. The criterion validity was 0.875. The Chinese version of MTBQ showed satisfactory reliability and validity in elderly patients with multimorbidity, and could be used as a tool to measure treatment burden of elderly patients with multimorbidity in hospital.

Sections du résumé

BACKGROUND BACKGROUND
Due to an ageing population, multimorbidity is becoming more common. Treatment burden (the effort required of patients to look after their health and the impact this has on their wellbeing) is prevalent in patients with multimorbidity. The Multimorbidity Treatment Burden Questionnaire (MTBQ) is a patient-reported outcome measure of treatment burden that has been validated amongst patients with multimorbidity in the UK. The aim of this study was to translate and culturally adapt the MTBQ into Chinese and to assess its reliability and validity in elderly patients with multimorbidity in hospital.
METHODS METHODS
The original English version of the MTBQ was translated into Chinese using Brislin's model of cross-culture translation. The C-MTBQ was piloted on a sample of 30 elderly patients with multimorbidity prior to being completed by 156 Chinese elderly patients with multimorbidity recruited from a hospital in Zhengzhou, China. We examined the proportion of missing data, the distribution of responses and floor and ceiling effects for each question. Factor analysis, Cronbach's alpha, intraclass coefficient and Spearman's rank correlations assessed dimensional structure, internal consistency reliability, test-retest reliability and criterion validity, respectively.
RESULTS RESULTS
The average age of the respondents was 73.5 years (range 60-99 years). The median C-MTBQ global score was 20.8 (interquartile range 12.5-29.2). Significant floor effects were seen for all items. Factor analysis supported a three-factor structure. The C-MTBQ had high internal consistency (Cronbach's alpha coefficient, 0.76) and test-retest reliability (the intraclass correlation coefficient, 0.944), the correlations between every item and global scores scored > 0.4. The scale content validity index(S-CVI) was 0.89, and the item level content validity index(I-CVI)was 0.83 ~ 1.00. The criterion validity was 0.875.
CONCLUSION CONCLUSIONS
The Chinese version of MTBQ showed satisfactory reliability and validity in elderly patients with multimorbidity, and could be used as a tool to measure treatment burden of elderly patients with multimorbidity in hospital.

Identifiants

pubmed: 32571343
doi: 10.1186/s12955-020-01395-z
pii: 10.1186/s12955-020-01395-z
pmc: PMC7310246
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

194

Références

Eur J Clin Pharmacol. 2018 Mar;74(3):357-364
pubmed: 29199370
Cell. 2014 Nov 6;159(4):709-13
pubmed: 25417146
J Clin Epidemiol. 1993 Dec;46(12):1417-32
pubmed: 8263569
BMJ Open. 2018 Apr 12;8(4):e019413
pubmed: 29654011
BMC Med. 2014 Jul 02;12:109
pubmed: 24989988
Eur J Health Econ. 2014 Dec;15(9):953-66
pubmed: 24292503
Br J Gen Pract. 2019 Sep 26;69(687):490
pubmed: 31558521
BMC Public Health. 2019 Sep 13;19(1):1267
pubmed: 31519162
Stat Methods Med Res. 2014 Oct;23(5):460-83
pubmed: 23427226
Patient Relat Outcome Meas. 2012;3:39-49
pubmed: 23185121
Health Qual Life Outcomes. 2019 Apr 11;17(1):62
pubmed: 30975148
BMC Neurol. 2019 Aug 27;19(1):209
pubmed: 31455235
BMC Health Serv Res. 2015 Jan 22;15:23
pubmed: 25609174
BMJ Open. 2018 Aug 29;8(8):e019845
pubmed: 30158215
Health Qual Life Outcomes. 2019 Jul 18;17(1):126
pubmed: 31319871
Ann Intern Med. 2001 Apr 17;134(8):663-94
pubmed: 11304107
Ann Fam Med. 2005 May-Jun;3(3):223-8
pubmed: 15928225
Hypertension. 2016 Mar;67(3):506-12
pubmed: 26865198
BMJ. 2014 Nov 10;349:g6680
pubmed: 25385748
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Value Health. 2008 May-Jun;11(3):509-21
pubmed: 18179659
Fam Pract. 2019 Oct 8;36(5):657-665
pubmed: 30820558
Cancer Nurs. 2017 Jan/Feb;40(1):E28-E35
pubmed: 26895416
Patient Educ Couns. 2019 Oct;102(10):1932-1938
pubmed: 31151781

Auteurs

Liyuan Dou (L)

School of Nursing and Health, Zhengzhou University, No.101, Kexue Road, Zhengzhou, Henan Province, 450000, People's Republic of China.

Juan Huang (J)

Party Secretary Office, People's Hospital of Zhengzhou, Zhengzhou, Henan Province, 450000, People's Republic of China. huangjuan1980@163.com.
Centre for Academic Primary Care, University of Bristol, Bristol, BS6 6HL, UK. huangjuan1980@163.com.

Polly Duncan (P)

Centre for Academic Primary Care, University of Bristol, Bristol, BS6 6HL, UK.

Lixiang Guo (L)

School of Nursing and Health, Zhengzhou University, No.101, Kexue Road, Zhengzhou, Henan Province, 450000, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH